

## REFERENCES

1. Remaley A, McNamara J, Warnick R. Lipids and lipoproteins. *Clinical chemistry: principles, procedures, correlations*. 2005: 282-313.
2. Rizzo M, Berneis K. Should we measure routinely the LDL peak particle size? *Int J Cardiol*. 2006; 107(2): 166-70.
3. Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. *J Lipid Res*. 1998; 39(6): 1263-73.
4. Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. *Am J Med*. 2001; 110(2): 103-10.
5. Packard C, Caslake M, Shepherd J. The role of small, dense low density lipoprotein (LDL): a new look. *Int J Cardiol*. 2000; 74 Suppl 1: S17-22.
6. Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. *Diabetes Metab*. 1999; 25(3): 199-211.
7. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. *Curr Opin Lipidol*. 1994; 5(6): 395-403.

8. Rohrer L, Hersberger M, von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. *Curr Opin Lipidol*. 2004; 15(3): 269-78.
9. Davidsson P, Hulthe J, Fagerberg B, Olsson BM, Hallberg C, Dahllof B, et al. A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. *J Lipid Res*. 2005; 46(9): 1999-2006.
10. Rifai N, Warnick GR, Remaley A. Lipids, Lipoproteins, Apolipoproteins and other cardiovascular risk factors. *Tietz Fundamentals of CLINICAL CHEMISTRY SIXTH EDITION*. 2007: 402-30.
11. Mroz R. Lipids. *Clinical chemistry: concepts & applications*. 2003: 179-202.
12. Clauss SB, Kwiterovich Jr PO. Genetic disorders of lipoprotein transport in children. *Prog Pediatric Cardiol*. 2003; 17(2): 123-33.
13. Rifai N, Bachorik P, Albers J. Lipids, Lipoproteins, and Apolipoproteins. *Fundamentals Clin Chem*. 2001: 462-93.
14. Myant N. LDL: Physical and Chemical Characteristics. *Cholesterol Metabolism, LDL, and the LDL Receptor*. 1990: 99-109.
15. Marenah C. Lipid metabolism, hyper- and hypolipidaemias. *Clinical biochemistry: metabolic and clinical aspects*. 2008: 749-82.
16. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. *Trends Mol Med*. 2011; 17(10): 594-603.

17. de Beer MC, Durbin DM, Cai L, Mirocha N, Jonas A, Webb NR, et al. Apolipoprotein A-II modulates the binding and selective lipid uptake of reconstituted high density lipoprotein by scavenger receptor BI. *J Biol Chem.* 2001; 276(19): 15832-9.
18. Hussain MM. A proposed model for the assembly of chylomicrons. *Atherosclerosis.* 2000; 148(1): 1-15.
19. Kendrick JS, Chan L, Higgins JA. Superior role of apolipoprotein B48 over apolipoprotein B100 in chylomicron assembly and fat absorption: an investigation of apobec-1 knock-out and wild-type mice. *Biochem J.* 2001; 356(Pt 3): 821-7.
20. Brouillette CG, Anantharamaiah GM, Engler JA, Borhani DW. Structural models of human apolipoprotein A-I: a critical analysis and review. *Biochim Biophys Acta.* 2001; 1531(1-2): 4-46.
21. Castellani L, Lusis A. ApoA-II Versus ApoA-I: Two for One Is Not Always a Good Deal. *Arterioscler Thromb Vasc Biol.* 2001; 21: 1870 - 2.
22. Rifai N, Bachorik P, Albers J. Lipids, lipoproteins and apolipoproteins. *Tietz textbook of clinical chemistry.* 1999; 3: 809-61.
23. Kwiterovich PO. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. *Am Cardiol.* 2002; 90: 30-47.
24. Superko H. Small, dense low-density lipoprotein subclass pattern B: Issues for the clinician. *Curr Atherosclerosis Rep.* 1999; 1(1): 50-7.

25. Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. *J Am Coll Cardiol.* 2007; 50(18): 1735-41.
26. Keaney JF, Jr., Vita JA. Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. *Prog Cardiovasc Dis.* 1995; 38(2): 129-54.
27. Ross R. Atherosclerosis--an inflammatory disease. *N Engl J Med.* 1999; 340(2): 115-26.
28. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. *JAMA.* 1988; 260(13): 1917-21.
29. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. *Arterioscler Thromb Vasc Biol.* 1996; 16(6): 763-72.
30. Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. *Clin Chem.* 2001; 47(2): 266-74.
31. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. *Clin Lab.* 2002; 48(3-4): 171-80.
32. Hirano T, Ito Y, Saegusa H, Yoshino G. A novel and simple method for quantification of small, dense LDL. *J Lipid Res.* 2003; 44(11): 2193-201.

33. Srisawasdi P, Chaloeysup S, Teerajetgul Y, Pocathikorn A, Sukasem C, Vanavanan S, et al. Estimation of plasma small dense LDL cholesterol from classic lipid measures. *Am J Clin Pathol*. 2011; 136(1): 20-9.
34. Finishing the euchromatic sequence of the human genome. *Nature*. 2004; 431(7011): 931-45.
35. Thermo Fisher Scientific Inc. Overview of Post-Translational Modifications (PTMs).
36. Montes M, Becerra S, Sanchez-Alvarez M, Sune C. Functional coupling of transcription and splicing. *Gene*. 2012; 501(2): 104-17.
37. Kashyap L, Tripathi P. Alternative splicing. *bioScience explained*. 2008; 4(1).
38. Walsh CT, Garneau-Tsodikova S, Gatto GJ, Jr. Protein posttranslational modifications: the chemistry of proteome diversifications. *Angew Chem Int Ed Engl*. 2005; 44(45): 7342-72.
39. Tuszynski GP, Buck CA, Warren L. A two-dimensional polyacrylamide gel electrophoresis (PAGE) system using sodium dodecyl sulfate-PAGE in the first dimension. *Anal Biochem*. 1979; 93(2): 329-38.
40. Nakamura K, Okuya Y, Katahira M, Yoshida S, Wada S, Okuno M. Analysis of tubulin isoforms by two-dimensional gel electrophoresis using SDS-polyacrylamide gel electrophoresis in the first dimension. *J Biochem Biophys Methods*. 1992; 24(3-4): 195-203.
41. Rabilloud T, Lelong C. Two-dimensional gel electrophoresis in proteomics: a tutorial. *J Proteomics*. 2011; 74(10): 1829-41.

42. Rabilloud T, Adessi C, Giraudel A, Lunardi J. Improvement of the solubilization of proteins in two-dimensional electrophoresis with immobilized pH gradients. *Electrophoresis*. 1997; 18(3-4): 307-16.
43. Hunter TC, Andon NL, Koller A, Yates JR, Haynes PA. The functional proteomics toolbox: methods and applications. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2002; 782(1-2): 165-81.
44. Westermeier R, Naven T. *Proteomics in Practice: A Laboratory Manual of Proteome Analysis*. *Electrophoresis in Practice*. 2002; 3.
45. Hochstrasser D, Augsburger V, Funk M, Appel R, Pellegrini C, Muller AF. Immobilized pH gradients in capillary tubes and two-dimensional gel Electrophoresis. 1986; 7(11): 505-11.
46. Patton WF. Protein detection and imaging in IEF gels. *Handbooks of Isoelectric Focusing and Proteomics*. 2005; 7: 165-80.
47. Miller I, Crawford J, Gianazza E. Protein stains for proteomic applications: which, when, why? *Proteomics*. 2006; 6(20): 5385-408.
48. Rabilloud T. Mechanisms of protein silver staining in polyacrylamide gels: a 10-year synthesis. *Electrophoresis*. 1990; 11(10): 785-94.
49. Rabilloud T, Vuillard L, Gilly C, Lawrence JJ. Silver-staining of proteins in polyacrylamide gels: a general overview. *Cell Mol Biol (Noisy-le-grand)*. 1994; 40(1): 57-75.
50. Rabilloud T. Silver Staining of 2D Electrophoresis Gels. *Methods Mol Biol*. 2012; 893: 61-73.
51. Patton WF. Detection technologies in proteome analysis. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2002; 771(1-2): 3-31.

52. Poland J, Rabilloud T, Sinha P. Silver Staining of 2-D Gels. *The Proteomics Protocols Handbook*. 2005: 177-84.
53. Sitex B, Scheibe B, Jung K, Schramm A, Stuehler K. Difference Gel Electrophoresis (DIGE): the Next Generation of Two-Dimensional Gel Electrophoresis for Clinical Research. *Proteomics Drug Res*. 2006: 33-55.
54. Fernandez-Patron C. Zn<sup>2+</sup> Reverse Staining Technique. *The Proteomics Protocols Handbook*. 2005: 185-90.
55. Castellanos-Serra LR, Fernandez-Patron C, Hardy E, Huerta V. A procedure for protein elution from reverse-stained polyacrylamide gels applicable at the low picomole level: An alternative route to the preparation of low abundance proteins for microanalysis. *Electrophoresis*. 1996; 17(10): 1564-72.
56. Shi Y, Xiang R, Horvath C, Wilkins JA. The role of liquid chromatography in proteomics. *J Chromatogr A*. 2004; 1053(1-2): 27-36.
57. Binz PA. Mass Spectrometry in Proteomics. *Genomics, Proteomics and Vaccines*. 2004.
58. March RE. Quadrupole ion trap mass spectrometry: a view at the turn of the century. *Int J Mass Spectrom*. 2000; 200(1-3): 285-312.
59. Veenstra TD. Mass Spectrometry: The Foundation of Proteomics. *Proteomics for Biological Discovery*. 2006.
60. Olson BJ, Markwell J. Assays for determination of protein concentration. *Curr Protoc Protein Sci*. 2007; Chapter 3: Unit 3 4.
61. Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. *Nat Med*. 2005; 11(4): 418-22.

62. Smith EE, Malik HS. The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions. *Genome Res.* 2009; 19(5): 850-8.
63. Vanhollebeke B, Pays E. The function of apolipoproteins L. *Cell Mol Life Sci.* 2006; 63(17): 1937-44.
64. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* 2002; 106(25): 3143-421.
65. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Arterioscler Thromb Vasc Biol.* 2004; 24(8): e149-61.
66. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. *Circulation.* 1997;95(1):69-75.
67. Sun HY, Chen SF, Lai MD, Chang TT, Chen TL, Li PY, et al. Comparative proteomic profiling of plasma very-low-density and low-density lipoproteins. *Clin Chim Acta.* 2010; 411(5-6): 336-44.
68. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. *Atherosclerosis.* 1998; 139(2): 205-22.



69. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. *Atherosclerosis*. 1996; 124(2): 261-71.
70. Olsson U, Camejo G, Hurt-Camejo E, Elfsber K, Wiklund O, Bondjers G. Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB/E receptor. *Arterioscler Thromb Vasc Biol*. 1997; 17(1): 149-55.
71. Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, Camejo G. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. *Arterioscler Thromb Vasc Biol*. 1997; 17(6): 1011-7.
72. Weisgraber KH, Rall SC, Jr., Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. *J Biol Chem*. 1981; 256(17): 9077-83.
73. Kesaniemi YA, Ehnholm C, Miettinen TA. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. *J Clin Invest*. 1987; 80(2): 578-81.
74. Gylling H, Kontula K, Miettinen TA. Cholesterol absorption and metabolism and LDL kinetics in healthy men with different apoprotein E phenotypes and apoprotein B Xba I and LDL receptor Pvu II genotypes. *Arterioscler Thromb Vasc Biol*. 1995; 15(2): 208-13.
75. Kolovou GD, Anagnostopoulou KK. Apolipoprotein E polymorphism, age and coronary heart disease. *Ageing Res Rev*. 2007; 6(2): 94-108.

76. Xu N, Dahlback B. A novel human apolipoprotein (apoM). *J Biol Chem.* 1999; 274(44): 31286-90.
77. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. *Proteomics.* 2005; 5(2): 551-65.
78. Christoffersen C, Jauhiainen M, Moser M, Porse B, Ehnholm C, Boesl M, et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. *J Biol Chem.* 2008; 283(4): 1839-47.
79. Ahnstrom J, Axler O, Jauhiainen M, Salomaa V, Havulinna AS, Ehnholm C, et al. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. *J Lipid Res.* 2008; 49(9): 1912-7.
80. Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, O'Connor PM, et al. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. *J Biol Chem.* 1997; 272(41): 25576-82.
81. Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. *Arterioscler Thromb Vasc Biol.* 2003; 23(5): 853-8.

82. Olin-Lewis K, Krauss RM, La Belle M, Blanche PJ, Barrett PH, Wight TN, et al. ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. *J Lipid Res.* 2002; 43(11): 1969-77.
83. Musunuru K, Orho-Melander M, Caulfield MP, Li S, Salameh WA, Reitz RE, et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. *Arterioscler Thromb Vasc Biol.* 2009; 29(11): 1975-80.
84. Ichikawa T, Kitajima S, Liang J, Koike T, Wang X, Sun H, et al. Overexpression of lipoprotein lipase in transgenic rabbits leads to increased small dense LDL in plasma and promotes atherosclerosis. *Lab Invest.* 2004; 84(6): 715-26.
85. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. *Circulation.* 1999; 99(15): 1959-64.
86. Qiu G, Ho AC, Yu W, Hill JS. Suppression of endothelial or lipoprotein lipase in THP-1 macrophages attenuates proinflammatory cytokine secretion. *J Lipid Res.* 2007; 48(2): 385-94.
87. Mendall MA, Carrington D, Strachan D, Patel P, Molineaux N, Levi J, et al. *Chlamydia pneumoniae*: risk factors for seropositivity and association with coronary heart disease. *J Infect.* 1995; 30(2): 121-8.
88. Memon RA, Staprans I, Noor M, Holleran WM, Uchida Y, Moser AH, et al. Infection and inflammation induce LDL oxidation *in vivo*. *Arterioscler Thromb Vasc Biol.* 2000; 20(6): 1536-42.

89. Dittrich R, Dragonas C, Mueller A, Maltaris T, Rupp J, Beckmann MW, et al. Endothelial *Chlamydia pneumoniae* infection promotes oxidation of LDL. *Biochem Biophys Res Commun.* 2004; 319(2): 501-5.
90. Pettersson C, Karlsson H, Stahlman M, Larsson T, Fagerberg B, Lindahl M, et al. LDL-associated apolipoprotein J and lysozyme are associated with atherogenic properties of LDL found in type 2 diabetes and the metabolic syndrome. *J Intern Med.* 2011; 269(3): 306-21.
91. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. *Proc Natl Acad Sci U S A.* 1994; 91(20): 9441-5.
92. Eichinger A, Nasreen A, Kim HJ, Skerra A. Structural insight into the dual ligand specificity and mode of high density lipoprotein association of apolipoprotein D. *J Biol Chem.* 2007; 282(42): 31068-75.
93. Perdomo G, Kim DH, Zhang T, Qu S, Thomas EA, Toledo FG, et al. A role of apolipoprotein D in triglyceride metabolism. *J Lipid Res.* 2010; 51(6): 1298-311.
94. Rickhag M, Deierborg T, Patel S, Ruscher K, Wieloch T. Apolipoprotein D is elevated in oligodendrocytes in the peri-infarct region after experimental stroke: influence of enriched environment. *J Cereb Blood Flow Metab.* 2008; 28(3): 551-62.
95. Wei YJ, Huang YX, Zhang XL, Li J, Huang J, Zhang H, et al. Apolipoprotein D as a novel marker in human end-stage heart failure: a preliminary study. *Biomarkers.* 2008; 13(5): 535-48.

96. Perdomo G, Henry Dong H. Apolipoprotein D in lipid metabolism and its functional implication in atherosclerosis and aging. *Aging (Albany NY)*. 2009; 1(1): 17-27.
97. Ganfornina MD, Do Carmo S, Lora JM, Torres-Schumann S, Vogel M, Allhorn M, et al. Apolipoprotein D is involved in the mechanisms regulating protection from oxidative stress. *Aging Cell*. 2008; 7(4): 506-15.
98. Christensen DJ, Ohkubo N, Oddo J, Van Kanegan MJ, Neil J, Li F, et al. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. *J Immunol*. 2011; 186(4): 2535-42.
99. Corthals GL, Wasinger VC, Hochstrasser DF, Sanchez JC. The dynamic range of protein expression: a challenge for proteomic research. *Electrophoresis*. 2000 ; 21(6): 1104-15.
100. Garfin DE. Two-dimensional gel electrophoresis: an overview. *Trends Analyt Chem*. 2003; 22(5): 263-72.
101. Lilley KS, Razzaq A, Dupree P. Two-dimensional gel electrophoresis: recent advances in sample preparation, detection and quantitation. *Curr Opin Chem Biol*. 2002; 6(1): 46-50.
102. Grove H, Faergestad EM, Hollung K, Martens H. Improved dynamic range of protein quantification in silver-stained gels by modelling gel images over time. *Electrophoresis*. 2009; 30(11): 1856-62.